BioPharmSignal logoBioPharmSignal

Biotech News

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis (OCS)OculisEarnings

Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven Path to Precision Medicine in Dry Eye Disease

Related news

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

LCTXLineage Cell Therapeutics2026-05-12 20:01 EST

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

OCGNOcugen2026-07-28 20:01 EST

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

PRQRProQR Therapeutics2026-05-12 11:00 EST

ProQR Announces First Quarter 2026 Operating and Financial Results

EYPTEyePoint Pharmaceuticals2026-05-06 11:00 EST

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

OCULOcular Therapeutix2026-05-05 11:00 EST

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

OCGNOcugen2026-04-29 11:02 EST

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

EYPTEyePoint Pharmaceuticals2026-08-05 11:00 EST

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

OCSOculis2026-08-03 08:00 EST

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

OCSOculis2026-07-08 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Stock data

Close
12.38 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States